Inhibition of p38α mitogen-activated protein kinase prevents the development of osteolytic bone disease, reduces tumor burden, and increases survival in murine models of multiple myelomaVANDERKERKEN, Karin; MEDICHERLA, Satya; CROUCHER, Peter I et al.Cancer research (Baltimore). 2007, Vol 67, Num 10, pp 4572-4577, issn 0008-5472, 6 p.Article

Delayed in vivo disease progression is associated with high proportions of CD45⁺ myeloma cells in the 5T2MM murine modelASOSINGH, Kewal; WILLEMS, Angelo; VAN RIET, Ivan et al.Cancer research (Baltimore). 2003, Vol 63, Num 12, pp 3019-3020, issn 0008-5472, 2 p.Article

Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myelomaVANDERKERKEN, Karin; DE LEENHEER, Evy; SHIPMAN, Claire et al.Cancer research (Baltimore). 2003, Vol 63, Num 2, pp 287-289, issn 0008-5472, 3 p.Article